Study: NCT03600909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).~A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.~A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).~A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.~A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).~A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.~A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin (Rabbit)
Description: Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin (Rabbit)
Description: Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin (Rabbit)
Description: Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The CliniMACS device
Description: The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The CliniMACS device
Description: The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The CliniMACS device
Description: The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: All patients will also receive G-CSF post-transplant to foster engraftment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: All patients will also receive G-CSF post-transplant to foster engraftment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: All patients will also receive G-CSF post-transplant to foster engraftment.